- Direct Relief is focused on providing diagnostic supplies, medicines, and medical equipment to improve care for people living with or at risk of HIV infection.
- Direct Relief equips front-line healthcare providers with supplies to provide HIV testing, treatment, and support for people living with or at risk of HIV infection.
- Direct Relief is collaborating with ministries of health and nongovernmental organizations internationally to expand access to HIV prevention and care.
While there has been a great deal of success, still far too many people are becoming infected with HIV, getting sick, and dying. In 2018, approximately 37.9 million people across the globe were living with HIV. A total of 1.7 million people were newly infected with HIV in 2018, and of those eligible for antiretroviral treatment, only 62 percent received the treatment they needed.
Treating Opportunistic Infections in People Living with HIV/AIDS
In 2010, Direct Relief became the implementing partner for the Diflucan® Partnership Program, a Pfizer global initiative that makes available Diflucan® to support treatment of opportunistic infections for people living with HIV. Diflucan® (fluconazole) is an essential anti-fungal medicine which has an important place in many National HIV/AIDS treatment programs. The Diflucan Partnership Program targets two opportunistic infections—esophageal candidiasis and cryptococcal meningitis—serious conditions with painful symptoms, and in the case of cryptococcal meningitis, can be life-threatening if gone untreated.
Diflucan® helps people living with HIV manage their opportunistic infections and promotes their ability to live more healthy, productive lives.